Why the study?
Large-scale genome-wide association studies had identified few SNPs associated with LV mass, prompting the use of a polygenic approach in a clinical population to identify risk factors and diseases linked to adverse LV remodeling.
Observational (n=66,439)
Yes
Answers are grounded in this paper and cite their sources.
A polygenic predictor of left ventricular mass is significantly associated with clinical diagnoses of cardiac diseases and modifiable risk factors such as obesity, hypertension, and coronary artery disease.
Left ventricular (LV) mass is a prognostic biomarker for incident heart disease and all-cause mortality. Large-scale genome-wide association studies have identified few SNPs associated with LV mass. We hypothesized that a polygenic discovery approach using LV mass measurements made in a clinical population would identify risk factors and diseases associated with adverse LV remodeling. We developed a polygenic single nucleotide polymorphism-based predictor of LV mass in 7,601 individuals with LV mass measurements made during routine clinical care. We tested for associations between this predictor and 894 clinical diagnoses measured in 58,838 unrelated genotyped individuals. There were 29 clinical phenotypes associated with the LV mass genetic predictor at FDR q < 0.05. Genetically predicted higher LV mass was associated with modifiable cardiac risk factors, diagnoses related to organ dysfunction and conditions associated with abnormal cardiac structure including heart failure and atrial fibrillation. Secondary analyses using polygenic predictors confirmed a significant association between higher LV mass and body mass index and, in men, associations with coronary atherosclerosis and systolic blood pressure. In summary, these analyses show that LV mass-associated genetic variability associates with diagnoses of cardiac diseases and with modifiable risk factors which contribute to these diseases.
No takes yet. Share an insight, caveat, or question.
Mosley et al. (2020) conducted an observational in Left ventricular mass and associated clinical phenotypes (n=66,439). Genetically predicted left ventricular mass vs. Lower genetically predicted left ventricular mass was evaluated on Cardiomegaly diagnosis (eMERGE validation set) (OR 1.10, 95% CI 1.06-1.14, p=4.1 x 10^-7).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: